Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - desvenlafaxine, quantity: 50 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; magnesium stearate; citric acid monohydrate; purified talc; povidone; alginic acid; hypromellose; titanium dioxide; macrogol 6000; iron oxide red - desvenlafaxine alembic is indicated for the treatment of major depressive disorder, including the prevention of relapse.,desvenlafaxine alembic is not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; alginic acid; purified talc; povidone; hypromellose; magnesium stearate; citric acid monohydrate; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - desvenlafaxine alembic is indicated for the treatment of major depressive disorder, including the prevention of relapse.,desvenlafaxine alembic is not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - venlafaxine hydrochloride, quantity: 169.8 mg (equivalent: venlafaxine, qty 150 mg) - capsule, modified release - excipient ingredients: gelatin; ethylcellulose; sunset yellow fcf; povidone; magnesium stearate; microcrystalline cellulose; brilliant blue fcf; copovidone; allura red ac; purified talc; colloidal anhydrous silica; titanium dioxide; propylene glycol; ethanol; isopropyl alcohol; shellac; tert-butyl alcohol; sodium hydroxide - venlafaxine alembic xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - venlafaxine hydrochloride, quantity: 84.9 mg (equivalent: venlafaxine, qty 75 mg) - capsule, modified release - excipient ingredients: iron oxide black; colloidal anhydrous silica; ethylcellulose; iron oxide red; magnesium stearate; microcrystalline cellulose; povidone; purified talc; titanium dioxide; gelatin; copovidone; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - venlafaxine alembic xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - venlafaxine hydrochloride, quantity: 42.45 mg (equivalent: venlafaxine, qty 37.5 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; copovidone; gelatin; magnesium stearate; titanium dioxide; povidone; iron oxide black; iron oxide yellow; colloidal anhydrous silica; purified talc; iron oxide red; ethylcellulose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - venlafaxine alembic xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - teriflunomide, quantity: 14 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; sodium starch glycollate type a; colloidal anhydrous silica; maize starch; purified water; microcrystalline cellulose; hyprolose; titanium dioxide; hypromellose; macrogol 8000; purified talc; indigo carmine aluminium lake - teriflunomide alembic is indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alembic products ltd - coconut oil fractionated - not applicable - 1ml/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - rivaroxaban, quantity: 10 mg - tablet, film coated - excipient ingredients: hypromellose; lactose monohydrate; microcrystalline cellulose; sodium lauryl sulfate; magnesium stearate; croscarmellose sodium; titanium dioxide; purified talc; macrogol 6000; iron oxide red - rivaroxaban is indicated for:,? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks),? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke,? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe,rivaroxaban, in combination with aspirin, is indicated for:,? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad)

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - rivaroxaban, quantity: 15 mg - tablet, film coated - excipient ingredients: poloxamer; croscarmellose sodium; hypromellose; lactose monohydrate; microcrystalline cellulose; magnesium stearate; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - rivaroxaban is indicated for:,? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks),? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke,? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe,rivaroxaban, in combination with aspirin, is indicated for:,? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad)

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - rivaroxaban, quantity: 2.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; hypromellose; magnesium stearate; sodium lauryl sulfate; titanium dioxide; iron oxide yellow; macrogol 6000; iron oxide red; quinoline yellow aluminium lake - rivaroxaban is indicated for:,? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks),? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke,? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe,rivaroxaban, in combination with aspirin, is indicated for:,? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad)